Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms including NAV4694, NAV5001, Manocept™ and NAV1800 (RIGScan™), to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care.
Type
Public
HQ
Dublin, US
Founded
1983
Size (employees)
56 (est)
Navidea Biopharmaceuticals was founded in 1983 and is headquartered in Dublin, US

Navidea Biopharmaceuticals Office Locations

Navidea Biopharmaceuticals has an office in Dublin
Dublin, US (HQ)
5600 Blazer Parkway,

Navidea Biopharmaceuticals Financials and Metrics

Navidea Biopharmaceuticals Financials

Navidea Biopharmaceuticals's revenue was reported to be $22 m in FY, 2016
USD

Revenue (Q1, 2017)

580 k

Gross profit (Q1, 2017)

580 k

Gross profit margin (Q1, 2017), %

100%

Net income (Q1, 2017)

85.6 m

EBIT (Q1, 2017)

(3.1 m)

Market capitalization (13-Nov-2017)

68.1 m

Cash (31-Mar-2017)

13.4 m
Navidea Biopharmaceuticals's current market capitalization is $68.1 m.
USDFY, 2016

Revenue

22 m

Cost of goods sold

2.3 m

Gross profit

19.7 m

Gross profit Margin, %

90%
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.1 m2.3 m2.1 m2.9 m4 m4.7 m5.4 m8.5 m580 k

Cost of goods sold

270.5 k807.9 k449.1 k332.7 k457.6 k534.9 k560.7 k921.8 k

Gross profit

804.2 k1.4 m1.7 m2.5 m3.5 m4.2 m4.8 m7.6 m580 k

Gross profit Margin, %

75%64%79%88%89%89%90%89%100%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

32.9 m5.5 m7.2 m1.5 m

Accounts Receivable

1.2 m816.5 k

Inventories

2.2 m1.5 m

Current Assets

37.3 m8.6 m12.6 m10.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

17.5 m10.4 m4.9 m15.8 m11.4 m5.5 m1.2 m810.4 k13.4 m

Accounts Receivable

487.1 k1.5 m1.2 m1.8 m1.9 m

Inventories

1.9 m1.1 m571.6 k1.2 m877.2 k898.9 k769.8 k804.9 k748

Current Assets

20.6 m14 m8 m19.5 m15 m10 m6.9 m9.4 m21.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(42.7 m)(35.7 m)(27.6 m)(14.3 m)

Accounts Receivable

(1 m)334.1 k

Inventories

(1.9 m)761 k136 k(861.3 k)

Accounts Payable

1 m(944.9 k)290 k5.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(22 m)(28.9 m)(7.3 m)(17 m)(25.1 m)(3.7 m)(10.4 m)(10.4 m)85.6 m

Depreciation and Amortization

235.4 k360.7 k149.8 k299.1 k431.4 k149.6 k267.4 k378.8 k86.5 k

Accounts Receivable

663.5 k(314.8 k)(394.5 k)(1 m)(1.1 m)903.1 k181.8 k210.5 k

Inventories

326.7 k573.2 k240.5 k(355.5 k)(83.7 k)(246 k)(116.9 k)(195.3 k)1.5 m
USDY, 2017

Revenue/Employee

10.4 k

Financial Leverage

1.5 x
Show all financial metrics

Navidea Biopharmaceuticals Market Value History

Navidea Biopharmaceuticals's Web-traffic and Trends

Navidea Biopharmaceuticals Company Life and Culture

You may also be interested in